- The FDA approves Vaxelis, a pediatric hexavalent combination vaccine developed as a JV between Sanofi (SNY +0.2%) and Merck (MRK +2%).
- The vaccine is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b in patients aged 6 weeks to 4 years.
- The companies are working to maximize production to meet U.S. demand will a commercial launch happening no sooner than 2020.